Short answer: So far, no. Animal studies suggested GLP-1 drugs protect neurons, but in people the large trials were negative. Oral semaglutide did not slow early Alzheimer’s (EVOKE and EVOKE+), liraglutide missed its main goal (ELAD), and exenatide did not slow Parkinson’s in a phase 3 trial. These drugs are not a dementia treatment.

There is no good evidence that GLP-1 drugs such as semaglutide (Ozempic, Wegovy) protect thinking or memory in people. The positive findings come from animal studies and observational registries, and the randomized trials that tested brain outcomes found no benefit.

This page is about research. It is not a guide to treating Alzheimer’s disease, Parkinson’s disease or diabetes. Diet is not a substitute for the treatment a doctor prescribes, and changes should be discussed with your care team. Do not start, stop or change any medication without medical advice.

On diet, in small studies fiber and eating protein before carbohydrates increased the body’s own GLP-1 release. This has not been shown to affect the brain.

What GLP-1 is and where it acts in the brain

GLP-1 (glucagon-like peptide-1) is a natural gut hormone. Cells in the lower small intestine and colon release it within minutes of eating, especially in response to glucose, amino acids and fatty acids. It boosts insulin release when blood sugar is high, lowers glucagon, slows stomach emptying and reduces hunger.

Natural GLP-1 lasts only about two minutes in the blood before the enzyme DPP-4 breaks it down. It reaches the brain mainly through the vagus nerve and through a few spots where the blood-brain barrier is leakier. Drugs such as semaglutide, liraglutide and tirzepatide are modified to resist DPP-4, which stretches their action from minutes to days or weeks.

GLP-1 receptors are found widely in the brain:

  • Hypothalamus: The main site of appetite suppression, the effect most people know from Ozempic.
  • Hippocampus: The memory center. In rats engineered to make more GLP-1 receptors there, learning and memory improved (During 2003). Mice lacking the receptor had a learning deficit that gene transfer to the hippocampus restored.
  • Reward areas: Receptors in the brain’s dopamine reward system lower the reward value of food. This may help explain why many people on semaglutide report fewer cravings. Whether this extends to other compulsive behaviors is being studied and remains preliminary.
  • Cortex, brainstem and a small area of the midbrain affected in Parkinson’s: Areas involved in planning, movement and automatic body functions.

What animal studies found

In cell and animal studies, GLP-1 drugs protected neurons in several ways. As the next section shows, this has not translated into benefit in human trials.

  • Inflammation and plaques: McClean and Hölscher (2014) gave liraglutide for two months to aged mice bred to develop Alzheimer’s-like changes. It improved spatial memory, cut plaque load by 33% and inflammation by 30%, and increased synapse numbers. In an earlier study (McClean 2011), liraglutide prevented memory impairment, reduced plaque counts by 40–50% and increased young neurons in the hippocampus of the same mouse strain.
  • Stroke and Parkinson’s models: Li (2009) found that the GLP-1 drug exendin-4 protected neurons against metabolic and oxidative damage, reduced brain damage after experimental stroke, and preserved dopamine neurons and movement in mice.
  • Dopamine neurons: Bertilsson (2008) found that exendin-4 promoted new neuron growth, increased cells with dopamine markers, and reduced abnormal movement in a rat model of Parkinson’s.

See neuroinflammation and diet for more on brain inflammation.

What trials in people found

Semaglutide in Alzheimer’s: EVOKE and EVOKE+

Novo Nordisk, which makes semaglutide, ran two large phase 3 trials: EVOKE (1,855 participants) and EVOKE+ (1,953 participants). They tested oral semaglutide (up to 14 mg daily) in people aged 55–85 with amyloid-confirmed mild cognitive impairment or mild dementia due to Alzheimer’s. They are the largest tests of a GLP-1 drug for neurodegeneration to date.

Both trials were negative. Novo Nordisk announced the results in November 2025, and they were published in The Lancet in 2026 (Cummings 2026). The main measure was the Clinical Dementia Rating-Sum of Boxes. At 104 weeks, decline was the same with semaglutide and placebo in both trials (p = 0.57 and p = 0.46). Semaglutide lowered C-reactive protein, a blood marker of inflammation, but that did not slow clinical decline. The trials were stopped.

Liraglutide in Alzheimer’s: ELAD

The ELAD trial (Edison 2026, Nature Medicine), led from Imperial College London, was a phase 2b trial in 204 people with mild to moderate Alzheimer’s and no diabetes. Participants took daily liraglutide injections or placebo for 52 weeks.

The main outcome, brain glucose use measured by PET scan, showed no significant difference between groups (p = 0.14). An executive-function score, a secondary outcome, was better with liraglutide (unadjusted p = 0.01), but daily activities and the Clinical Dementia Rating did not differ. A positive secondary result in a trial that missed its main goal is a lead for research, not evidence of benefit.

Exenatide in Parkinson’s

In a single-center trial (Athauda 2017), 62 people with moderate Parkinson’s took exenatide 2 mg once weekly or placebo for 48 weeks, then stopped for 12 weeks. At 60 weeks, off-medication motor scores had improved by 1.0 point with exenatide and worsened by 2.1 points with placebo, an adjusted difference of 3.5 points (p = 0.03). The authors said it was uncertain whether this reflected an effect on the disease or a long-lasting effect on symptoms.

A larger phase 3 trial did not confirm it. Vijiaratnam (2025) randomized 194 people with Parkinson’s at six UK hospitals to exenatide 2 mg weekly or placebo for 96 weeks. Motor scores worsened by 5.7 points with exenatide and 4.5 points with placebo (p = 0.47), so there was no evidence that exenatide slows the disease. In 2026, The Lancet attached an expression of concern to this paper after an inspection raised concerns about trial conduct at one site. Investigations were ongoing at the time of writing. More on diet in Parkinson’s disease.

Registry studies in people with diabetes

Nørgaard (2022) looked at people with type 2 diabetes in two data sources. In pooled data from three heart outcome trials (15,820 patients), dementia diagnoses were less common with a GLP-1 drug than with placebo (hazard ratio 0.47). Those trials were not designed to measure dementia. In a Danish national registry of 120,054 patients, each extra year on a GLP-1 drug was associated with an 11% lower dementia rate. Several authors were Novo Nordisk employees.

Registry studies cannot prove cause, because people prescribed these drugs may differ from other diabetes patients. The negative EVOKE trials show that these associations did not predict benefit in people who already have early Alzheimer’s. Whether the drugs lower dementia risk in cognitively healthy people with diabetes remains untested.

Metabolism, insulin and the brain

Obesity, insulin resistance and type 2 diabetes are themselves independent risk factors for cognitive decline and dementia. GLP-1 drugs reduce weight, improve blood sugar control and insulin resistance, and lower inflammation in the body. So when registry studies show lower dementia rates, it is hard to tell how much comes from direct action on the brain and how much from better metabolic health. Both are plausible.

Some researchers have called Alzheimer’s “type 3 diabetes” because brain insulin resistance plays a prominent role. When brain insulin signaling is impaired, neurons become more vulnerable to damage, amyloid clearance is reduced and tau changes speed up. That is why researchers hoped GLP-1 drugs would slow neurodegeneration, a hope the EVOKE trials did not support. See also blood sugar and brain function.

Can diet raise your own GLP-1?

To some degree. Your body releases GLP-1 every time you eat, and the amount depends on what you eat. The levels are far lower than with drugs, and no study has shown that diet-driven GLP-1 changes affect the brain.

  • Fermentable fiber: Gut bacteria turn it into short-chain fatty acids. In colon cell cultures and in mice, these triggered GLP-1 release through the receptors FFAR2 and FFAR3 (Tolhurst 2012). Sources include oats, barley, lentils, chickpeas, black beans, Jerusalem artichokes, garlic, onions, leeks, asparagus and psyllium husk.
  • Protein first: In a GLP-1-producing cell line, the amino acid glutamine stimulated GLP-1 release more strongly than glucose (Reimann 2004). A small crossover trial in Japan included 12 people with type 2 diabetes and 10 healthy volunteers. Eating fish or meat before rice increased GLP-1 and lowered the post-meal glucose rise compared with rice first (Kuwata 2016). Sources include eggs, fish, poultry, legumes, Greek yogurt and tofu.
  • Fats: In lab studies, some fatty acids stimulate GLP-1 release. Human evidence for specific fats is limited.
  • Fermented foods: These have been proposed to raise GLP-1 indirectly by supporting bacterial fatty acid production. We found no human trials showing this.
  • Polyphenols: Some raised GLP-1 in cell and animal studies; a grape seed extract increased active GLP-1 after a glucose drink in rats (González-Abuín 2014). Human data are limited.

These habits fit within the Mediterranean diet for brain health. None has been tested for effects on the brain:

  • Eat protein before carbohydrates (this increased GLP-1 in one small trial).
  • Include fermentable fiber at every meal.
  • Choose whole, minimally processed foods, and limit ultra-processed food, which tends to be low in fiber and protein.
  • Use extra virgin olive oil as your main fat, and eat fatty fish two to three times a week.
  • Include fermented foods daily.

People taking insulin or other glucose-lowering medicines should discuss large diet changes with their doctor, because changes in meal composition can affect blood sugar.

What we still don’t know

  • Long-term brain effects: These drugs have been used widely for well over a decade, but there is little long-term data on brain structure, function or dementia risk in people without dementia.
  • Dose: It is unclear whether the doses that cause weight loss are the ones that would be needed for brain effects, or whether higher, more brain-penetrant doses would be required.
  • Side effects: Nausea, vomiting and other gut side effects are common, especially while the dose is being raised, and some people stop the drug because of them.
  • Hype: The drugs’ commercial success creates incentives to find brain benefits. So far the story follows a familiar Alzheimer’s pattern: promise in animals and observational data, then negative results in definitive trials.

As of late 2026, researchers are examining EVOKE biomarker data and subgroups, and testing newer dual and triple agonists such as tirzepatide and retatrutide. Brain-imaging substudies are running within obesity and diabetes trials. Other studies ask whether semaglutide crosses the blood-brain barrier in useful amounts or acts mainly through the vagus nerve.

Frequently Asked Questions

Should I take Ozempic or Wegovy for brain health?

No. GLP-1 drugs are approved for type 2 diabetes and obesity (and some for cardiovascular risk reduction), not for cognition or neuroprotection. Oral semaglutide did not slow early Alzheimer’s in EVOKE and EVOKE+. If you have diabetes or obesity, make decisions about these medications with your doctor.

Do GLP-1 drugs affect mood or mental health?

Some patients report mood changes, both positive and negative. The European Medicines Agency’s safety committee began a review in July 2023. In April 2024 it concluded that the evidence did not support a causal link with suicidal thoughts or actions, and monitoring continues. Anyone with low mood or suicidal thoughts while taking any medicine should contact their doctor promptly.

Is GLP-1 part of the gut-brain axis?

Yes. GLP-1 is a gut hormone that signals to the brain partly through the vagus nerve, and bacterial products such as short-chain fatty acids stimulate its release in lab studies. Read more about the gut-brain axis.

Sources

  • Athauda, D., Maclagan, K., Skene, S. S., et al. (2017). Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. The Lancet, 390(10103), 1664-1675. doi:10.1016/S0140-6736(17)31585-4
  • Vijiaratnam, N., Girges, C., Auld, G., et al. (2025). Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. The Lancet, 405(10479), 627-636. doi:10.1016/S0140-6736(24)02808-3 (Expression of concern: The Lancet, 2026, 407(10548), 2588, doi:10.1016/S0140-6736(26)01241-9)
  • Cummings, J. L., Atri, A., Sano, M., et al. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet, 407(10544), 2167-2179. doi:10.1016/S0140-6736(26)00459-9
  • Bertilsson, G., Patrone, C., Zachrisson, O., et al. (2008). Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson’s disease. Journal of Neuroscience Research, 86(2), 326-338. doi:10.1002/jnr.21483
  • During, M. J., Cao, L., Zuzga, D. S., et al. (2003). Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature Medicine, 9(9), 1173-1179. doi:10.1038/nm919
  • Edison, P., Femminella, G. D., Ritchie, C., et al. (2026). Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial. Nature Medicine, 32(1), 353-361. doi:10.1038/s41591-025-04106-7
  • González-Abuín, N., Martínez-Micaelo, N., Margalef, M., et al. (2014). A grape seed extract increases active glucagon-like peptide-1 levels after an oral glucose load in rats. Food & Function, 5(9), 2357-2364. doi:10.1039/c4fo00447g
  • Kuwata, H., Iwasaki, M., Shimizu, S., et al. (2016). Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial. Diabetologia, 59(3), 453-461. doi:10.1007/s00125-015-3841-z
  • Li, Y., Perry, T., Kindy, M. S., et al. (2009). GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences, 106(4), 1285-1290. doi:10.1073/pnas.0806720106
  • McClean, P. L., & Hölscher, C. (2014). Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology, 76(Pt A), 57-67. doi:10.1016/j.neuropharm.2013.08.005
  • McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. The Journal of Neuroscience, 31(17), 6587-6594. doi:10.1523/JNEUROSCI.0529-11.2011
  • Nørgaard, C. H., Friedrich, S., Hansen, C. T., et al. (2022). Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 8(1), e12268. doi:10.1002/trc2.12268
  • Reimann, F., Williams, L., da Silva Xavier, G., Rutter, G. A., & Gribble, F. M. (2004). Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia, 47(9), 1592-1601. doi:10.1007/s00125-004-1498-0
  • Tolhurst, G., Heffron, H., Lam, Y. S., et al. (2012). Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes, 61(2), 364-371. doi:10.2337/db11-1019